Samsung Biologics to Build 4th Plant in Songdo with 1.7 Trillion KRW Investment (Update)
![[Image source=Yonhap News]](http://www.asiae.co.kr/news/img_view.htm?img=2018111417345027963_1542184491.jpg)
[Asia Economy Reporter Cho Hyun-ui] Samsung Biologics announced on the 11th that it will establish a 4th plant for biopharmaceutical production in Songdo, Incheon.
Kim Tae-han, CEO of Samsung Biologics, held an online press conference that morning and made the announcement.
The investment amount is 1.74 trillion KRW, with a completion target set for 2023. Upon completion, the production facility capacity of the 4th plant will be 256,000 liters. The purpose of the investment is to strengthen competitiveness by expanding biopharmaceutical production facilities.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
CEO Kim said, "The 4th plant will change the paradigm of the bio industry not only in scale but also in functionality."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
